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Determination of primary nonfunction (PNF) of a liver transplant can be one of the most difficult 
assessments in transplantation. PNF can initially manifest in variety of ways both dramatic and 
subtle, and no one parameter is sufficient for diagnosis [1,2].  The determination of PNF informs 
the decision to relist for a second liver transplant. Once relisted, one or more additional 
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confirmations are subsequently necessary in the context of deciding whether to retransplant as 
donors become available. In addition, a retransplant operation is not without risk, especially in 
the setting of the existing or impending multiorgan system failure that can be associated with 
PNF. On the other hand, an incorrect decision to not retransplant can lead to profoundly adverse 
short and long term outcomes. For these reasons, the need for accurate real-time prediction of 
PNF is critically important, to ensure appropriate use of organs but most importantly to make the 
best choices for a critically ill transplant recipient.  
 
Existing criteria are helpful but have limitations in their ability to identify PNF, and the 
determination remains heavily dependent on clinical judgement. By logistical necessity, many 
operational definitions of PNF align with those established for urgent liver allocation. Both UK 
and US criteria incorporate AST, INR and acidosis/lactate, but with different thresholds and 
algorithms [3,4]. However, because of the imperfect predictive power of these criteria, there are 
numerous examples of recipients meeting criteria who are not clinically judged to have PNF and 
who uneventfully recover, and unfortunately others who do not meet criteria who are judged to 
have sufficient dysfunction to warrant retransplantation.  In the US the latter can be 
accomplished through the high MELD scores often found in these patients, but ideally these 
recipients would have the more expanded access to donor livers associated with 1A status. 
 
In this issue of AJT, Al-Freah, et al. have developed a model of PNF using lab based parameters 
that improves upon existing methods [5]. The formula includes only biochemical parameters, and 
utilizes data over 7 days – albumin at transplant, day-1 AST, day-1 lactate, day-3 bilirubin, day-3 
INR and day-7 AST were identified as independent factors associated with PNF. The model was 
able to predict PNF as defined by death or retransplant within two weeks with significantly 
superior performance over current criteria in the United Kingdom (UK) and United States (US) 
(model AUROC of 0.912 vs. UK PNF criteria of 0.669 and US criteria of .774). The model was 
also able to predict PNF at 3 days, albeit with less accuracy, and thus can be also used early after 
transplant. By expanding the timeframe for defining PNF to two weeks after transplant, the 
authors have built in potential utility in borderline cases that may have less urgency, but are no 
less important to evaluate. With substantially improved performance in predicting PNF, this easy 
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to use model has the potential to have an important impact in the management of early graft 
dysfunction. 
 
There are several noteworthy methodological features. One is the decision to eliminate 
modifiable variables such as renal function or renal replacement therapy. While more sound in 
the derivation of the model by eliminating practice variations that might introduce bias, from an 
application perspective it leaves out a potentially important predictor that could influence 
recipient outcomes. It is somewhat reassuring that including creatinine and renal replacement did 
not appreciably alter model performance, and was not predictive of outcome. Second is the 
exclusion of hepatic artery thrombosis (HAT) from the cohort, under the rationale that HAT is 
sufficient to consider retransplantation by itself. This leaves out an important population whose 
outcomes are variable enough that they could benefit from a predictive tool for subsequent PNF. 
 
The most important caveat in assessing the potential impact of this work is the lack of a perfect 
endpoint, or gold standard, for defining PNF. Although death is clearly defined, retransplantation 
is determined by clinical practice; thus the model is influenced by selection biases and could be 
simply reaffirming current UK clinical practices. It is important to note that in this study, these 
practices were guided by existing UK relisting criteria and are at least likely to be internally 
consistent. Nevertheless, this unavoidable limitation only highlights the need for external 
validation through multicenter investigations in other allocation systems and countries before 
broad application can be recommended. 
 
Regardless of the predictive ability of a lab-based model, determinations of PNF will still require 
consideration of other less quantifiable factors and reasoned and experienced clinical judgment. 
However, this effort represents a possible adjunct to such judgment, and a potentially significant 
step forward in the difficult and high-stakes process of determining PNF. 
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